Unlocking the Potential of Therapeutics for Fibrosis & Oncology Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
View Top Employees from Nuformix PlcWebsite | http://www.nuformix.com |
Ticker | NFX |
Revenue | $774000 |
Employees | 5 (2 on RocketReach) |
Founded | 2008 |
Phone | +44 1223 627222 |
Technologies |
JavaScript,
HTML,
Twitter
+16 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Pharmaceutical, Biotechnology, Manufacturing, Health Care |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Nuformix Plc employee's phone or email?
The Nuformix Plc annual revenue was $774000 in 2024.
Frederick Gawn is the CEO of Nuformix Plc.
2 people are employed at Nuformix Plc.
The NAICS codes for Nuformix Plc are [3254, 32541, 32, 325].
The SIC codes for Nuformix Plc are [28, 283].